Literature DB >> 9568713

Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions.

D Shmerling1, I Hegyi, M Fischer, T Blättler, S Brandner, J Götz, T Rülicke, E Flechsig, A Cozzio, C von Mering, C Hangartner, A Aguzzi, C Weissmann.   

Abstract

The physiological role of prion protein (PrP) remains unknown. Mice devoid of PrP develop normally but are resistant to scrapie; introduction of a PrP transgene restores susceptibility to the disease. To identify the regions of PrP necessary for this activity, we prepared PrP knockout mice expressing PrPs with amino-proximal deletions. Surprisingly, PrP lacking residues 32-121 or 32-134, but not with shorter deletions, caused severe ataxia and neuronal death limited to the granular layer of the cerebellum as early as 1-3 months after birth. The defect was completely abolished by introducing one copy of a wild-type PrP gene. We speculate that these truncated PrPs may be nonfunctional and compete with some other molecule with a PrP-like function for a common ligand.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9568713     DOI: 10.1016/s0092-8674(00)81572-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  190 in total

1.  Immobilized prion protein undergoes spontaneous rearrangement to a conformation having features in common with the infectious form.

Authors:  E Leclerc; D Peretz; H Ball; H Sakurai; G Legname; A Serban; S B Prusiner; D R Burton; R A Williamson
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

2.  Dominant-negative inhibition of prion formation diminished by deletion mutagenesis of the prion protein.

Authors:  L Zulianello; K Kaneko; M Scott; S Erpel; D Han; F E Cohen; S B Prusiner
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor.

Authors:  C Hundt; J M Peyrin; S Haïk; S Gauczynski; C Leucht; R Rieger; M L Riley; J P Deslys; D Dormont; C I Lasmézas; S Weiss
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

Review 4.  The molecular pathology of CJD: old and new variants.

Authors:  G S Jackson; J Collinge
Journal:  Mol Pathol       Date:  2001-12

5.  Grand ideas floating freely. Conference on the new prion biology: basic science, diagnosis and therapy.

Authors:  Bruce Chesebro
Journal:  EMBO Rep       Date:  2002-12       Impact factor: 8.807

6.  Identification of a novel gene encoding a PrP-like protein expressed as chimeric transcripts fused to PrP exon 1/2 in ataxic mouse line with a disrupted PrP gene.

Authors:  A Li; S Sakaguchi; R Atarashi; B C Roy; R Nakaoke; K Arima; N Okimura; J Kopacek; K Shigematsu
Journal:  Cell Mol Neurobiol       Date:  2000-10       Impact factor: 5.046

7.  Prion infection impairs the cellular response to oxidative stress.

Authors:  O Milhavet; H E McMahon; W Rachidi; N Nishida; S Katamine; A Mangé; M Arlotto; D Casanova; J Riondel; A Favier; S Lehmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 8.  Insights into Mechanisms of Transmission and Pathogenesis from Transgenic Mouse Models of Prion Diseases.

Authors:  Julie A Moreno; Glenn C Telling
Journal:  Methods Mol Biol       Date:  2017

9.  De novo generation of a transmissible spongiform encephalopathy by mouse transgenesis.

Authors:  Christina J Sigurdson; K Peter R Nilsson; Simone Hornemann; Mathias Heikenwalder; Giuseppe Manco; Petra Schwarz; David Ott; Thomas Rülicke; Pawel P Liberski; Christian Julius; Jeppe Falsig; Lothar Stitz; Kurt Wüthrich; Adriano Aguzzi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-10       Impact factor: 11.205

10.  NADPH oxidase and extracellular regulated kinases 1/2 are targets of prion protein signaling in neuronal and nonneuronal cells.

Authors:  Benoît Schneider; Vincent Mutel; Mathéa Pietri; Myriam Ermonval; Sophie Mouillet-Richard; Odile Kellermann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.